Veracyte to Participate in Upcoming Investor Conferences

VCYT 10.30.2024

Full Press ReleaseSEC FilingsOur VCYT Tweets

About Gravity Analytica

Recent News

  • 12.05.2024 - Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Recent Filings

  • 01.10.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
  • 01.08.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.02.2025 - 144 Report of proposed sale of securities

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 30, 2024--Veracyte, Inc.(Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences.

  • UBS Healthcare Conference–Rancho Palos Verdes, CAFireside Chat onNovember 12that2:45 p.m. Eastern Time
  • Guggenheim Inaugural Healthcare Innovation Conference–Boston, MAFireside Chat onNovember 13that3:00 p.m. Eastern Time
  • Wolfe Research Healthcare Conference–New York, NYFireside Chat onNovember 19that1:40 p.m. Eastern Time
  • Stephens Annual Investor Conference –Nashville, TNFireside Chat onNovember 20that4:00 p.m. Eastern Time

Live audio webcasts of the company’s presentations will be available by visiting Veracyte’s website athttp://investor.veracyte.com/events-presentations. Replays of the webcasts will be available for 90 days after each live presentation broadcast.

AboutVeracyte

Veracyte(Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visitwww.veracyte.comor follow us onLinkedInorX (Twitter).

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241029391463/en/

Investors:Shayla Gormaninvestors@veracyte.com(619) 393-1545

Media:Tracy Morrismedia@veracyte.com(650) 380-4413

Source:Veracyte, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com